SEC Form SCHEDULE 13G filed by Entera Bio Ltd.
$ENTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Entera Bio Ltd. (Name of Issuer) |
Ordinary Shares Nominal value of NIS 0.0000769 per share (Title of Class of Securities) |
M40527109 (CUSIP Number) |
03/16/2025 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
 Rule 13d-1(c)
|
| Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | M40527109 |
| 1 | Names of Reporting Persons
OPKO HEALTH, INC. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
3,685,226.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
8.1 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: Based on 45,420,676 shares of ordinary shares of the Issuer outstanding on March 20, 2025, as set forth in the Issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 28, 2025.
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Entera Bio Ltd. | |
| (b) | Address of issuer's principal executive offices:
KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM, ISRAEL, 9112002. | |
| Item 2. | ||
| (a) | Name of person filing:
OPKO Health, Inc. (the "Reporting Person") | |
| (b) | Address or principal business office or, if none, residence:
4400 Biscayne Blvd., Miami, FL 33137 | |
| (c) | Citizenship:
State of Delaware | |
| (d) | Title of class of securities:
Ordinary Shares Nominal value of NIS 0.0000769 per share | |
| (e) | CUSIP No.:
M40527109 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for the Reporting Person and is incorporated herein by reference.
The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 45,420,676 shares of ordinary shares of the Issuer outstanding on March 20, 2025, as set forth in the Issuer's Form 10-K filed with the SEC on March 28, 2025.
| |
| (b) | Percent of class:
8.1%
The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 45,420,676 shares of ordinary shares of the Issuer outstanding on March 20, 2025, as set forth in the Issuer's Form 10-K filed with the SEC on March 28, 2025.
| |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
3,685,226 Shares | ||
| (ii) Shared power to vote or to direct the vote:
- | ||
| (iii) Sole power to dispose or to direct the disposition of:
3,685,226 | ||
| (iv) Shared power to dispose or to direct the disposition of:
- | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|